Detalhe da pesquisa
1.
Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.
Hepatology
; 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38381705
2.
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
Oncologist
; 23(1): 2-e5, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158365
3.
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Oncologist
; 22(10): 1158-e116, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28687627
4.
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol
; 15(11): 1791-1799, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28579181
5.
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
Cancer
; 119(18): 3334-42, 2013 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23821538
6.
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction.
Mol Carcinog
; 52 Suppl 1: E139-47, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23776098
7.
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
Oncologist
; 17(7): 937-46, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22622147
8.
Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States.
Hepatology
; 49(5): 1563-70, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19399911
9.
Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study.
Int J Cancer
; 123(8): 1883-91, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18688864
10.
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
Cancer Med
; 6(9): 2042-2051, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801995
11.
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.
J Clin Oncol
; 23(28): 7125-34, 2005 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16192596
12.
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
J Clin Oncol
; 21(3): 421-7, 2003 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12560429
13.
Treatment of hepatocellular carcinoma in the community: disparities in standard therapy.
Liver Cancer
; 4(1): 70-83, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26020030
14.
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Cancer Chemother Pharmacol
; 66(2): 287-94, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19855966
15.
The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.
J Hepatol
; 50(2): 334-41, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19070394
16.
A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.
J Cancer Res Clin Oncol
; 134(12): 1325-35, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18504614
17.
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.
Am J Gastroenterol
; 102(5): 1016-21, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17324130
18.
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Am J Clin Oncol
; 30(4): 350-7, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17762434
19.
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Cancer
; 103(4): 749-55, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15660400
20.
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
Am J Clin Oncol
; 28(4): 334-9, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16062073